Stockreport

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax

Aptose Biosciences, Inc. - Common Shares  (APTO) 
Last aptose biosciences, inc. - common shares earnings: 3/10 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: aptose.com/investors
PDF Peer-reviewed publication details unique TUS mechanism of action TUS+VEN combination synthetic lethality overcomes resistance to VEN Tuspetinib prolongs survival i [Read more]